At its Q1/2019 update, Vicore confirmed that all pipeline projects are on track. VP01 is expected to enter Phase IIa trials in idiopathic pulmonary fibrosis ("IPF") and diffuse systemic sclerosis ("dSSc") in H2/2019E, while VP02 is undergoing formulation work and should start a first-in-human trial in 2020E. From a financial point of view, Vicore reported an operating loss of SEK16m, more than double the SEK7.2m incurred in the prior year, primarily reflecting the higher cost base of the enlarge ....
17 May 2019
Key activities on track at Q1/2019 update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Key activities on track at Q1/2019 update
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
17 May 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
At its Q1/2019 update, Vicore confirmed that all pipeline projects are on track. VP01 is expected to enter Phase IIa trials in idiopathic pulmonary fibrosis ("IPF") and diffuse systemic sclerosis ("dSSc") in H2/2019E, while VP02 is undergoing formulation work and should start a first-in-human trial in 2020E. From a financial point of view, Vicore reported an operating loss of SEK16m, more than double the SEK7.2m incurred in the prior year, primarily reflecting the higher cost base of the enlarge ....